Trial · NCT04338022
Adverse events174
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 174
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Leukopenia | Blood and lymphatic system disorders | Teriflunomide | 39 | 563 | 66 |
| other | Leukopenia | Blood and lymphatic system disorders | Evobrutinib | 13 | 559 | 15 |
| other | Neutropenia | Blood and lymphatic system disorders | Teriflunomide | 41 | 563 | 87 |
| other | Neutropenia | Blood and lymphatic system disorders | Evobrutinib | 20 | 559 | 23 |
| other | Diarrhoea | Gastrointestinal disorders | Teriflunomide | 53 | 563 | 71 |
| other | Diarrhoea | Gastrointestinal disorders | Evobrutinib | 15 | 559 | 20 |
| other | Fatigue | General disorders | Teriflunomide | 32 | 563 | 34 |
| other | Fatigue | General disorders | Evobrutinib | 29 | 559 | 33 |
| other | COVID-19 | Infections and infestations | Teriflunomide | 108 | 563 | 117 |
| other | COVID-19 | Infections and infestations | Evobrutinib | 121 | 559 | 142 |
| other | Nasopharyngitis | Infections and infestations | Teriflunomide | 61 | 563 | 82 |
| other | Nasopharyngitis | Infections and infestations | Evobrutinib | 67 | 559 | 105 |
| other | Upper respiratory tract infection | Infections and infestations | Teriflunomide | 42 | 563 | 62 |
| other | Upper respiratory tract infection | Infections and infestations | Evobrutinib | 36 | 559 | 56 |
| other | Urinary tract infection | Infections and infestations | Teriflunomide | 26 | 563 | 32 |
| other | Urinary tract infection | Infections and infestations | Evobrutinib | 36 | 559 | 56 |
| other | Alanine aminotransferase increased | Investigations | Teriflunomide | 86 | 563 | 134 |
| other | Alanine aminotransferase increased | Investigations | Evobrutinib | 77 | 559 | 131 |
| other | Aspartate aminotransferase increased | Investigations | Teriflunomide | 54 | 563 | 71 |
| other | Aspartate aminotransferase increased | Investigations | Evobrutinib | 51 | 559 | 66 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04338022/events